Literature DB >> 17211632

The medial and lateral substantia nigra in Parkinson's disease: mRNA profiles associated with higher brain tissue vulnerability.

D C Duke1, L B Moran, R K B Pearce, M B Graeber.   

Abstract

Sporadic Parkinson's disease (PD) is characterized by progressive death of dopaminergic neurons within the substantia nigra. However, pathological cell death within this nucleus is not uniform. In PD, the lateral tier of the substantia nigra (SNl) degenerates earlier and more severely than the more medial nigral component (SNm). The cause of this brain regional vulnerability remains unknown. We have used DNA oligonucleotide microarrays to compare gene expression profiles from the SNl to those of the SNm in both PD and control cases. Genes expressed more highly in the PD SNl included the cell death gene, p53 effector related to PMP22, the tumour necrosis factor (TNF) receptor gene, TNF receptor superfamily, member 21, and the mitochondrial complex I gene, NADH dehydrogenase (ubiquinone) 1beta subcomplex, 3, 12 kDa (NDUFbeta3). Genes that were more highly expressed in PD SNm included the dopamine cell signalling gene, cyclic adenosine monophosphate-regulated phosphoprotein, 21 kDa, the activated macrophage gene, stabilin 1, and two glutathione peroxidase (GPX) genes, GPX1 and GPX3. Thus, there is increased expression of genes encoding pro-inflammatory cytokines and subunits of the mitochondrial electron transport chain, and there is a decreased expression of several glutathione-related genes in the SNl suggesting a molecular basis for pathoclisis. Importantly, some of the genes that are differentially regulated in the SNl are known to be expressed highly or predominantely in glial cells. These findings support the view that glial cells can be primarily affected in PD emphasizing the importance of using a whole tissue approach when investigating degenerative CNS disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17211632     DOI: 10.1007/s10048-006-0077-6

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  61 in total

1.  The human genome: gene expression profiling and schizophrenia.

Authors:  K Mirnics; F A Middleton; D A Lewis; P Levitt
Journal:  Am J Psychiatry       Date:  2001-09       Impact factor: 18.112

Review 2.  Metabolism and functions of glutathione in brain.

Authors:  R Dringen
Journal:  Prog Neurobiol       Date:  2000-12       Impact factor: 11.685

3.  Tumor necrosis factor gene polymorphisms in patients with sporadic Parkinson's disease.

Authors:  M Nishimura; I Mizuta; E Mizuta; S Yamasaki; M Ohta; R Kaji; S Kuno
Journal:  Neurosci Lett       Date:  2001-09-21       Impact factor: 3.046

4.  Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease.

Authors:  Krishnan Sriram; Joanna M Matheson; Stanley A Benkovic; Diane B Miller; Michael I Luster; James P O'Callaghan
Journal:  FASEB J       Date:  2002-07-18       Impact factor: 5.191

5.  Dopamine transporter mRNA: dense expression in ventral midbrain neurons.

Authors:  S Shimada; S Kitayama; D Walther; G Uhl
Journal:  Brain Res Mol Brain Res       Date:  1992-05

6.  Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.

Authors:  J Sian; D T Dexter; A J Lees; S Daniel; Y Agid; F Javoy-Agid; P Jenner; C D Marsden
Journal:  Ann Neurol       Date:  1994-09       Impact factor: 10.422

7.  Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease.

Authors:  G Boka; P Anglade; D Wallach; F Javoy-Agid; Y Agid; E C Hirsch
Journal:  Neurosci Lett       Date:  1994-05-19       Impact factor: 3.046

8.  Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP.

Authors:  J S Schneider; A Yuwiler; C H Markham
Journal:  Brain Res       Date:  1987-05-12       Impact factor: 3.252

9.  Altered proteasomal function in sporadic Parkinson's disease.

Authors:  Kevin St P McNaught; Roger Belizaire; Ole Isacson; Peter Jenner; C Warren Olanow
Journal:  Exp Neurol       Date:  2003-01       Impact factor: 5.330

10.  Lateromedial gradient of the susceptibility of midbrain dopaminergic neurons to neonatal 6-hydroxydopamine toxicity.

Authors:  H Okamura; C Yokoyama; Y Ibata
Journal:  Exp Neurol       Date:  1995-12       Impact factor: 5.330

View more
  40 in total

Review 1.  Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.

Authors:  Malú G Tansey; Melissa K McCoy; Tamy C Frank-Cannon
Journal:  Exp Neurol       Date:  2007-07-17       Impact factor: 5.330

Review 2.  Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease.

Authors:  L Holper; D Ben-Shachar; J J Mann
Journal:  Neuropsychopharmacology       Date:  2018-05-16       Impact factor: 7.853

3.  Biased Oxytocinergic Modulation of Midbrain Dopamine Systems.

Authors:  Lei Xiao; Michael F Priest; Jordan Nasenbeny; Ting Lu; Yevgenia Kozorovitskiy
Journal:  Neuron       Date:  2017-06-29       Impact factor: 17.173

4.  The nature of working memory gating in Parkinson's disease: A multi-domain signal detection examination.

Authors:  Mitchell G Uitvlugt; Timothy J Pleskac; Susan M Ravizza
Journal:  Cogn Affect Behav Neurosci       Date:  2016-04       Impact factor: 3.282

5.  Regulation of microglia effector functions by tumor necrosis factor signaling.

Authors:  Ashley S Harms; Jae-Kyung Lee; Thi A Nguyen; Jianjun Chang; Kelly M Ruhn; Isaac Treviño; Malú G Tansey
Journal:  Glia       Date:  2011-10-11       Impact factor: 7.452

Review 6.  Current status and future directions of gene expression profiling in Parkinson's disease.

Authors:  James G Greene
Journal:  Neurobiol Dis       Date:  2010-11-05       Impact factor: 5.996

Review 7.  Parkinson's disease and enhanced inflammatory response.

Authors:  Iva Stojkovska; Brandon M Wagner; Brad E Morrison
Journal:  Exp Biol Med (Maywood)       Date:  2015-03-13

8.  Parkinson's Disease Master Regulators on Substantia Nigra and Frontal Cortex and Their Use for Drug Repositioning.

Authors:  D M Vargas; M A De Bastiani; R B Parsons; F Klamt
Journal:  Mol Neurobiol       Date:  2020-11-19       Impact factor: 5.590

9.  Selective neuronal vulnerability to oxidative stress in the brain.

Authors:  Xinkun Wang; Elias K Michaelis
Journal:  Front Aging Neurosci       Date:  2010-03-30       Impact factor: 5.750

10.  Histone H4 deacetylation plays a critical role in early gene silencing during neuronal apoptosis.

Authors:  Heather R Pelzel; Cassandra L Schlamp; Robert W Nickells
Journal:  BMC Neurosci       Date:  2010-05-26       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.